Phase II Trial Using Erbitux + Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 31 Mar 2017 Status changed from completed to discontinued.
- 08 Aug 2016 Status changed from recruiting to completed.
- 25 Jul 2013 Planned end date changed from 1 Apr 2018 to 1 May 2018 as reported by ClinicalTrials.gov.